Regeneron Pharmaceuticals and Sanofi said they will charge $37,000 annually in the U.S. for their newly approved eczema drug, a price the companies said they reached after months of negotiations with pharmacy benefit managers.

NEXT
Sections:  business   
Topics:  health   
RELATED ARTICLES
  • no title provided in feed
    Americans' mental health issues are not identified and treated as readily as physical symptoms, especially among children - in part due to a shortage of clinicians. "We're looking for ways to integrate mental health into settings where children and families are every day," says Dr. More
  • no title provided in feed
    Mayor Donna Deegan speaks with CNN's Jake Tapper More
  • no title provided in feed
    Rep. Brad Wenstrup speaks with CNN's Jake Tapper More
  • no title provided in feed
    For some who see a therapist, just talking things through isn't enough. Drama therapy allows the patient to relive a moment or play out their biggest fears. More
  • no title provided in feed
    Sen. Mark Kelly joins The Lead More
  • no title provided in feed
    This year, 28,000 pounds of human waste was removed from base camp. The Mount Everest Biogas Project plans to convert this waste into a usable product. More
BING NEWS:
  • AbbVie's Rinvoq conquers Regeneron and Sanofi's Dupixent in eczema trial—again
    For the second time in four years, AbbVie’s Rinvoq (upadacitinib) has shown superior efficacy to Regeneron and Sanofi’s powerhouse Dupixent (dupilumab) in a head-to-head study in patients with atopic ...
    04/26/2024 - 12:39 am | View Link
  • AbbVie's Rinvoq Shows Positive Results Over Dupixent In Atopic Dermatitis Study
    AbbVie Inc. (ABBV) reported positive results from the Phase 3b/4 LEVEL UP study comparing the effectiveness and safety of ...
    04/25/2024 - 5:14 am | View Link
  • AbbVie’s skin disease drug found to be more effective than Regeneron’s Dupixent in study
    AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to ...
    04/25/2024 - 4:11 am | View Link
  • More

 

NEXT
Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

Movies With Butter More Movie News

More News